BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.
about
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyMitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating DrugsData Analysis for High-Throughput RNAi Screening.The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells.Rational Combinations of Targeted Agents in AMLInhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemiaApoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients.Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.Targeting prohibitins induces apoptosis in acute myeloid leukemia cells.MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylationComplementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cellsRational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies.Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome.A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy.Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignanciesSequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.5-Azacytidine specifically inhibits the NIH-3T3 PCD process induced by TNF-alpha and cycloheximide via affecting BCL-XL.Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.Combined venetoclax and alvocidib in acute myeloid leukemia.The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.Pathways and mechanisms of venetoclax resistance.In Vitro High-Throughput RNAi Screening to Accelerate the Process of Target Identification and Drug Development.Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AMLVitamin C promotes decitabine or azacytidine induced DNA hydroxymethylation and subsequent reactivation of the epigenetically silenced tumour suppressor in colon cancer cellsVenetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell TransplantEfficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
P2860
Q26749870-EA2E59E7-DA49-4EC5-A856-C00266888E80Q28548058-9B931FE1-1777-454E-BD63-FD324A349885Q31125921-2FCFEAF9-6978-4396-BEFF-D3324760FE9BQ34436545-0D82F646-6DFA-4FD3-8753-871290F595BEQ35750491-6C7EDD12-B7D6-4812-AC4F-3DB490BEB32FQ35859229-8AE74E6E-53F7-47BE-A64D-84A545F2E065Q36003724-BA429271-D7E5-4CB8-99ED-F3222F261D24Q36190177-62469D91-8C42-4972-8353-C5E424A965EEQ36208342-A454530E-A320-4BDF-98C5-74ABE9CDE949Q37376388-97557400-387A-4610-A523-4CF202FDF89FQ37662175-1C6B0E4C-5FEB-4269-A187-8306CB54F12EQ37676956-B9921C58-C3D3-4D78-8803-0DE4EAD09777Q37725409-D4814478-AD03-4B05-A1C0-3DE83CC13249Q38637652-BF4B96A2-0CA4-4826-B813-7058C8B1C612Q38715325-D9511FFF-938E-4722-984E-28ABED5F299FQ38874826-EDF482CA-785B-492E-9618-147C33D2EC5FQ38924940-9F9F8645-D515-464C-ABCE-F63F4E41E655Q39007037-F88ABE09-BE27-4E99-8413-E80447589F5EQ40139200-1FEE922A-CE8B-4445-904B-42AFD64D403AQ40759493-258B7858-76D2-4D68-9619-A7C1BBF37355Q41009977-EF084909-3074-4611-B183-F4776D7C6E1FQ42798512-78B128B8-4C39-459E-BE20-770586ACAD0AQ46370948-D5BF8BFE-C366-4F5B-9DDF-CB21EE31AC83Q47105216-32D5D0F8-8366-49AA-A964-EA42E1D3CEB6Q48121335-459FCB00-F569-436D-96DE-4EFAE9EE1D82Q51160342-20338285-10AF-470B-8B65-BA7CD237CA46Q52851340-81B3CB0F-8A28-4868-BE46-19936F184C39Q55379234-07BC35C8-E0B6-4414-98FB-945250D2AFA6Q58562912-5F060CC9-DA44-4157-853F-DAEAAD3D297EQ58697697-77BAFA97-27F2-4323-AE0B-8CFFC40ACACCQ58702132-7F6968CC-5F06-4ECE-A926-4B10E5569E01Q58776910-E9A91F89-DF0C-4EFE-8075-91BDFB8EC05A
P2860
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
BCL-2 family proteins as 5-Aza ...... ponse in myeloid malignancies.
@en
BCL-2 family proteins as 5-Aza ...... ponse in myeloid malignancies.
@nl
type
label
BCL-2 family proteins as 5-Aza ...... ponse in myeloid malignancies.
@en
BCL-2 family proteins as 5-Aza ...... ponse in myeloid malignancies.
@nl
prefLabel
BCL-2 family proteins as 5-Aza ...... ponse in myeloid malignancies.
@en
BCL-2 family proteins as 5-Aza ...... ponse in myeloid malignancies.
@nl
P2093
P2860
P50
P356
P1433
P1476
BCL-2 family proteins as 5-Aza ...... sponse in myeloid malignancies
@en
P2093
A Choudhary
A K Stewart
D O Azorsa
I M Gonzales
J Camoriano
P2860
P2888
P304
P356
10.1038/LEU.2014.44
P577
2014-01-23T00:00:00Z